Development of 186/188Re-Chitosan as an Effective Therapeutic Agent for Rheumatoid Arthritis.
CONCLUSION: According to the results, there is a possibility of labeling rhenium with chitosan in very high radiochemical purity. Regarding the high retention of these radiopharmaceuticals in joints with no leakage to surrounding organs, 186/188Re-chitosan can be applied as new radiosynovectomy drugs for rheumatoid arthritis treatment.
PMID: 33272191 [PubMed - as supplied by publisher]
Source: Current Radiopharmaceuticals - Category: Radiology Tags: Curr Radiopharm Source Type: research
More News: Arthritis | Chronic Pain | Disability | Pain | Radiology | Rheumatoid Arthritis | Rheumatology | Study